Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.

Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, Quartuccio L, Egan CG, Lo Monaco A, Benucci M, Salaffi F, Semeraro A, Parisi S, Ceccarelli F, Piazza I, Foti R.

Rheumatol Int. 2019 Aug 21. doi: 10.1007/s00296-019-04416-3. [Epub ahead of print]

PMID:
31435754
2.

Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities.

Rock BM, Foti RS.

Drug Metab Dispos. 2019 Oct;47(10):1097-1099. doi: 10.1124/dmd.119.088708. Epub 2019 Aug 9.

PMID:
31399505
3.

Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species.

Foti RS, Biswas K, Aral J, Be X, Berry L, Cheng Y, Conner K, Falsey JR, Glaus C, Herberich B, Hickman D, Ikotun T, Li H, Long J, Huang L, Miranda LP, Murray J, Moyer B, Netirojjanakul C, Nixey TE, Sham K, Soto M, Tegley CM, Tran L, Wu B, Yin L, Rock DA.

Drug Metab Dispos. 2019 Oct;47(10):1111-1121. doi: 10.1124/dmd.119.087742. Epub 2019 Aug 6.

PMID:
31387871
4.

An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab.

Scrivo R, Giardino AM, Salvarani C, Foti R, Afeltra A, Viapiana O, Giacomelli R, Salaffi F, Galeazzi M, Ramonda R, Ciccia F, Valesini G, Iannone F; Predicting MDA in PsA Study Group.

Clin Exp Rheumatol. 2019 Jul 8. [Epub ahead of print]

PMID:
31287400
5.

Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment.

Costa L, Ramonda R, Ortolan A, Favero M, Foti R, Visalli E, Rossato M, Cacciapaglia F, Lapadula G, Scarpa R.

Clin Rheumatol. 2019 Sep;38(9):2355-2362. doi: 10.1007/s10067-019-04663-6. Epub 2019 Jun 28.

PMID:
31264033
6.

Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling.

Liu Z, Osipovitch M, Benraiss A, Huynh NPT, Foti R, Bates J, Chandler-Militello D, Findling RL, Tesar PJ, Nedergaard M, Windrem MS, Goldman SA.

Cell Rep. 2019 Jun 25;27(13):3832-3843.e6. doi: 10.1016/j.celrep.2019.05.088.

7.

[Work on a building site at high altitude: physiopathological features and entailments for the occupational medicine].

Taino G, Giardini G, Delogu A, Foti R, Oddone E, Imbriani M.

G Ital Med Lav Ergon. 2019 Jul;41(3):242-252. Italian.

8.

Human pharmaceuticals in three major fish species from the Uruguay River (South America) with different feeding habits.

Rojo M, Álvarez-Muñoz D, Dománico A, Foti R, Rodriguez-Mozaz S, Barceló D, Carriquiriborde P.

Environ Pollut. 2019 Sep;252(Pt A):146-154. doi: 10.1016/j.envpol.2019.05.099. Epub 2019 May 20.

PMID:
31146229
9.

Competing Conversations: An Examination of Competition as Intrateam Interactions.

Abraham EK, McCusker ME, Foti RJ.

Front Psychol. 2019 May 3;10:970. doi: 10.3389/fpsyg.2019.00970. eCollection 2019.

10.

Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics.

Murray JK, Wu B, Tegley CM, Nixey TE, Falsey JR, Herberich B, Yin L, Sham K, Long J, Aral J, Cheng Y, Netirojjanakul C, Doherty L, Glaus C, Ikotun T, Li H, Tran L, Soto M, Salimi-Moosavi H, Ligutti J, Amagasu S, Andrews KL, Be X, Lin MJ, Foti RS, Ilch CP, Youngblood B, Kornecook TJ, Karow M, Walker KW, Moyer BD, Biswas K, Miranda LP.

ACS Chem Biol. 2019 Apr 19;14(4):806-818. doi: 10.1021/acschembio.9b00183. Epub 2019 Mar 27.

PMID:
30875193
11.

Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach.

Visalli E, Crispino N, Foti R.

Adv Ther. 2019 Apr;36(4):806-816. doi: 10.1007/s12325-019-00901-0. Epub 2019 Feb 25. Review.

PMID:
30805821
12.

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.

Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11.

PMID:
30767865
13.

"Disease knowledge index" and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases.

Andreoli L, Lazzaroni MG, Carini C, Dall'Ara F, Nalli C, Reggia R, Rodrigues M, Benigno C, Baldissera E, Bartoloni-Bocci E, Basta F, Bellisai F, Bortoluzzi A, Campochiaro C, Cantatore FP, Caporali R, Ceribelli A, Chighizola CB, Conigliaro P, Corrado A, Cutolo M, D'Angelo S, De Stefani E, Doria A, Favaro M, Fischetti C, Foti R, Gabrielli A, Generali E, Gerli R, Gerosa M, Larosa M, Maier A, Malavolta N, Meroni M, Meroni PL, Montecucco C, Mosca M, Padovan M, Paolazzi G, Pazzola G, Peccatori S, Perricone R, Pettiti G, Picerno V, Prevete I, Ramoni V, Romeo N, Ruffatti A, Salvarani C, Sebastiani GD, Selmi C, Serale F, Sinigaglia L, Tani C, Trevisani M, Vadacca M, Valentini E, Valesini G, Visalli E, Vivaldelli E, Zuliani L, Tincani A.

Joint Bone Spine. 2019 Jul;86(4):475-481. doi: 10.1016/j.jbspin.2018.12.002. Epub 2018 Dec 21.

PMID:
30579917
14.

The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.

Conti F, Atzeni F, Massaro L, Chiara Gerardi M, Gremese E, Passiu G, Carletto A, Malavolta N, Foti R, Ramonda R, Sarzi-Puttini P.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii11-vii22. doi: 10.1093/rheumatology/key209. Review.

PMID:
30289537
15.

1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.

Boezio AA, Andrews K, Boezio C, Chu-Moyer M, Copeland KW, DiMauro EF, Foti RS, Fremeau RT Jr, Gao H, Geuns-Meyer S, Graceffa RF, Gunaydin H, Huang H, La DS, Ligutti J, Moyer BD, Peterson EA, Yu V, Weiss MM.

Bioorg Med Chem Lett. 2018 Jun 15;28(11):2103-2108. doi: 10.1016/j.bmcl.2018.04.035. Epub 2018 Apr 17.

PMID:
29709252
16.

Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans.

Wong T, Wang Z, Chapron BD, Suzuki M, Claw KG, Gao C, Foti RS, Prasad B, Chapron A, Calamia J, Chaudhry A, Schuetz EG, Horst RL, Mao Q, de Boer IH, Thornton TA, Thummel KE.

Drug Metab Dispos. 2018 Apr;46(4):367-379. doi: 10.1124/dmd.117.078428. Epub 2018 Jan 17.

17.

The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis.

Salaffi F, Di Carlo M, Iannone F, Fedele AL, Epis OM, Pellerito R, Foti R, Passiu G, Punzi L, Furini F, Sarzi-Puttini P, Carletto A, Gremese E, Lapadula G, Ferraccioli G.

Semin Arthritis Rheum. 2018 Apr;47(5):619-629. doi: 10.1016/j.semarthrit.2017.09.013. Epub 2017 Sep 28.

PMID:
29102157
18.

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.

Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G.

Clin Rheumatol. 2018 Feb;37(2):315-321. doi: 10.1007/s10067-017-3846-8. Epub 2017 Oct 5.

PMID:
28980085
19.

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group.

Joint Bone Spine. 2018 Jul;85(4):455-459. doi: 10.1016/j.jbspin.2017.08.003. Epub 2017 Sep 8.

PMID:
28893679
20.

Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.

Schenkel LB, DiMauro EF, Nguyen HN, Chakka N, Du B, Foti RS, Guzman-Perez A, Jarosh M, La DS, Ligutti J, Milgram BC, Moyer BD, Peterson EA, Roberts J, Yu VL, Weiss MM.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3817-3824. doi: 10.1016/j.bmcl.2017.06.054. Epub 2017 Jun 26.

PMID:
28684121
21.

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.

Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28413099
22.

Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement".

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Nguyen HN, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2017 Feb 28;8(3):378. doi: 10.1021/acsmedchemlett.7b00075. eCollection 2017 Mar 9.

23.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM.

J Med Chem. 2017 Jul 27;60(14):5990-6017. doi: 10.1021/acs.jmedchem.6b01850. Epub 2017 Apr 20.

PMID:
28324649
24.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT Jr.

J Med Chem. 2017 Jul 27;60(14):5969-5989. doi: 10.1021/acs.jmedchem.6b01851. Epub 2017 Apr 20.

PMID:
28287723
25.

Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.

Caporali R, Carletto A, Conti F, D'Angelo S, Foti R, Gremese E, Govoni M, Iannone F, Pellerito R, Sinigaglia L.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):772-776. Epub 2017 Mar 3.

PMID:
28281459
26.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2016 Sep 21;7(12):1062-1067. eCollection 2016 Dec 8. Erratum in: ACS Med Chem Lett. 2017 Feb 28;8(3):378.

27.

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Sparling BA, Yi S, Able J, Bregman H, DiMauro EF, Foti RS, Gao H, Guzman-Perez A, Huang H, Jarosh M, Kornecook T, Ligutti J, Milgram BC, Moyer BD, Youngblood B, Yu VL, Weiss MM.

Medchemcomm. 2016 Dec 2;8(4):744-754. doi: 10.1039/c6md00578k. eCollection 2017 Apr 1.

28.

Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.

Foti R, Visalli E, Amato G, Benenati A, Converso G, Farina A, Bellofiore S, Mulè M, Di Gangi M.

Rheumatol Int. 2017 Feb;37(2):245-249. doi: 10.1007/s00296-016-3582-4. Epub 2016 Oct 28.

29.

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM.

J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.

PMID:
27441383
31.

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).

Gonzalez-Lopez de Turiso F, Hao X, Shin Y, Bui M, Campuzano ID, Cardozo M, Dunn MC, Duquette J, Fisher B, Foti RS, Henne K, He X, Hu YL, Kelly RC, Johnson MG, Lucas BS, McCarter J, McGee LR, Medina JC, Metz D, San Miguel T, Mohn D, Tran T, Vissinga C, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang X, Cushing TD.

J Med Chem. 2016 Aug 11;59(15):7252-67. doi: 10.1021/acs.jmedchem.6b00827. Epub 2016 Jul 25.

PMID:
27411843
32.

Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.

Foti RS, Dalvie DK.

Drug Metab Dispos. 2016 Aug;44(8):1229-45. doi: 10.1124/dmd.116.071753. Epub 2016 Jun 13. Erratum in: Drug Metab Dispos. 2016 Sep;44(9):1516.

PMID:
27298339
33.

Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D.

J Pharmacol Exp Ther. 2016 May;357(2):281-92. doi: 10.1124/jpet.116.232637. Epub 2016 Mar 2.

34.

Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study.

Colombo D, Chimenti S, Grossi PA, Marchesoni A, Foti R, Calzavara-Pinton P, Zagni E, Ori A, Bellia G; SYNERGY Study Group.

G Ital Dermatol Venereol. 2017 Jun;152(3):297-301. doi: 10.23736/S0392-0488.16.05301-3. Epub 2016 Feb 2.

PMID:
26837484
35.

Nuclear Architecture Organized by Rif1 Underpins the Replication-Timing Program.

Foti R, Gnan S, Cornacchia D, Dileep V, Bulut-Karslioglu A, Diehl S, Buness A, Klein FA, Huber W, Johnstone E, Loos R, Bertone P, Gilbert DM, Manke T, Jenuwein T, Buonomo SC.

Mol Cell. 2016 Jan 21;61(2):260-73. doi: 10.1016/j.molcel.2015.12.001. Epub 2015 Dec 24.

36.

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the TAilored BIOlogic therapy (ITABIO).

Semin Arthritis Rheum. 2016 Apr;45(5):519-32. doi: 10.1016/j.semarthrit.2015.10.001. Epub 2015 Oct 22. Review.

PMID:
26607440
37.

Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.

Duan H, Hu T, Foti RS, Pan Y, Swaan PW, Wang J.

Drug Metab Dispos. 2015 Nov;43(11):1773-80. doi: 10.1124/dmd.115.064824. Epub 2015 Aug 18.

38.

An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database.

Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A, Denaro V, Carreira P, Varju C, Gabrielli B, Zingarelli S, Caramaschi P, Simic-Pasalic K, Müller-Ladner U, Vasile M, Mihai C, Rosato E, Vacca A, Zenone T, Mohamed WA, Ancuta C, Zampogna G, Rednic S, Jabaar N, Belloli L, Pozzi MR, Foti R, Walker UA; EUSTAR Co-Investigators.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S47-54. Epub 2015 Aug 5.

PMID:
26243652
39.

Long-term survival in a patient with muscle-eye-brain disease.

Falsaperla R, Giunta L, Lubrano R, Foti R, Vitaliti G.

Neurol Sci. 2015 Nov;36(11):2147-9. doi: 10.1007/s10072-015-2321-z. Epub 2015 Jul 8. No abstract available.

PMID:
26152802
40.

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, Baldari G, De Filippo M, Ferretti S, Moroni G, Foti R, Di Gangi M, Jeannin G, Saffroy R, Emile JF, Buzio C, Vaglio A.

Blood. 2015 Sep 3;126(10):1163-71. doi: 10.1182/blood-2015-01-620377. Epub 2015 Jun 3.

41.

"Target-Site" Drug Metabolism and Transport.

Foti RS, Tyndale RF, Garcia KL, Sweet DH, Nagar S, Sharan S, Rock DA.

Drug Metab Dispos. 2015 Aug;43(8):1156-68. doi: 10.1124/dmd.115.064576. Epub 2015 May 18.

PMID:
25986849
42.

Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.

Topletz AR, Tripathy S, Foti RS, Shimshoni JA, Nelson WL, Isoherranen N.

Mol Pharmacol. 2015;87(3):430-41. doi: 10.1124/mol.114.096784. Epub 2014 Dec 9. Erratum in: Mol Pharmacol. 2020 Jan;97(1):1.

43.

Long-term efficacy of adalimumab in hyperimmunoglobulin D and periodic fever syndrome.

Di Gangi M, Amato G, Converso G, Benenati A, Leonetti C, Borella E, Doria A, Foti R.

Isr Med Assoc J. 2014 Oct;16(10):605-7. No abstract available.

44.

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.

Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).

Joint Bone Spine. 2014 Dec;81(6):508-12. doi: 10.1016/j.jbspin.2014.06.011. Epub 2014 Jul 28.

PMID:
25082646
45.

Characterization of the active site properties of CYP4F12.

Eksterowicz J, Rock DA, Rock BM, Wienkers LC, Foti RS.

Drug Metab Dispos. 2014 Oct;42(10):1698-707. doi: 10.1124/dmd.114.059626. Epub 2014 Jul 29.

PMID:
25074871
46.

Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.

Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2014 Jun;95(6):653-62. doi: 10.1038/clpt.2014.50. Epub 2014 Feb 25.

47.

Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study.

Ghrénassia E, Avouac J, Khanna D, Derk CT, Distler O, Suliman YA, Airo P, Carreira PE, Foti R, Granel B, Berezne A, Cabane J, Ingegnoli F, Rosato E, Caramaschi P, Hesselstrand R, Walker UA, Alegre-Sancho JJ, Zarrouk V, Agard C, Riccieri V, Schiopu E, Gladue H, Steen VD, Allanore Y.

J Rheumatol. 2014 Jan;41(1):99-105. doi: 10.3899/jrheum.130386. Epub 2013 Dec 1.

PMID:
24293584
48.

High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adami S, Cantini F, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis).

Clin Rheumatol. 2014 Jan;33(1):31-7. doi: 10.1007/s10067-013-2348-6. Epub 2013 Aug 18.

PMID:
23954923
49.

Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy.

Rossini M, D'Avola G, Muratore M, Malavolta N, Silveri F, Bianchi G, Frediani B, Minisola G, Sorgi ML, Varenna M, Foti R, Tartarelli G, Orsolini G, Adami S; Study Group on Osteoporosis and Metabolic Skeletal Diseases of the Italian Society of Rheumatology (SIR).

Reumatismo. 2013 Jul 23;65(3):113-20. doi: 10.4081/reumatismo.2013.113.

50.

Signs of critical transition in the Everglades wetlands in response to climate and anthropogenic changes.

Foti R, del Jesus M, Rinaldo A, Rodriguez-Iturbe I.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6296-300. doi: 10.1073/pnas.1302558110. Epub 2013 Apr 1.

Supplemental Content

Support Center